TrialCancer medicine2020

Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.

Akira Ooki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.